A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

par Csonka, Denes, Hazell, Katharine, Waldron, Edward, Lorenzo, Sebastien, Duval, Vincent, Trandafir, Lucia, Kobalava, Zhanna D.
Publié dans J Clin Pharmacol (2016)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

par Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Publié dans Onco Targets Ther (2016)

ATNT-12 PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND...

par Rodon, Jordi, Rosenthal, Mark, Mason, Warren, Segura, Pedro Perez, Beck, Joseph T., Hirte, Holger, DeGroot, John F., Trandafir, Lucia, Pognan, Nathalie, Yang, Lin, Kanwal, Charu, Wen, Patrick Y.
Publié dans Neuro Oncol (2015)

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases...

par Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.
Publié dans Prostate (2019)